Cooper Companies (NASDAQ:COO) Stock Rating Upgraded by Barclays

Cooper Companies (NASDAQ:COO) was upgraded by investment analysts at Barclays to a “hold” rating in a research note issued on Wednesday, Zacks reports.

A number of other research analysts also recently commented on COO. Bank of America reissued a “neutral” rating and issued a $65.00 price target (down from $80.00) on shares of Cooper Companies in a report on Thursday, September 10th. Wells Fargo & Company set a $61.00 price objective on Cooper Companies and gave the stock an “equal weight” rating in a report on Thursday, September 10th. Stifel Nicolaus set a $70.00 target price on Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. William Blair downgraded shares of Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Finally, Mizuho set a $75.00 price target on shares of Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Cooper Companies has an average rating of “Hold” and an average price target of $68.60.

Cooper Companies Price Performance

COO opened at $54.30 on Wednesday. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 2.23 and a beta of 0.83. The company has a current ratio of 1.22, a quick ratio of 0.73 and a debt-to-equity ratio of 0.23. The company has a fifty day simple moving average of $65.64 and a 200 day simple moving average of $66.74.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm’s revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities research analysts expect that Cooper Companies will post 4.53 EPS for the current fiscal year.

Cooper Companies declared that its board has approved a share buyback program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Cooper Companies

In other news, Director Paul Keel bought 4,701 shares of Cooper Companies stock in a transaction on Friday, September 11th. The shares were bought at an average price of $53.18 per share, with a total value of $249,999.18. Following the acquisition, the director directly owned 4,701 shares in the company, valued at approximately $249,999.18. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lawrence Kurzius bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The stock was purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the transaction, the director owned 31,099 shares in the company, valued at approximately $1,708,268.07. This represents a 47.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 34,701 shares of company stock worth $1,880,039 over the last quarter. 2.08% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cooper Companies

Large investors have recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. increased its stake in Cooper Companies by 112.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock valued at $1,132,000 after purchasing an additional 8,366 shares during the last quarter. HBK Investments L P acquired a new position in shares of Cooper Companies in the 2nd quarter valued at about $31,666,000. Sequoia Financial Advisors LLC boosted its holdings in shares of Cooper Companies by 290.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after buying an additional 25,504 shares during the period. Tidal Investments LLC grew its position in shares of Cooper Companies by 281.4% during the 2nd quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock valued at $5,945,000 after buying an additional 61,165 shares during the last quarter. Finally, National Pension Service raised its stake in Cooper Companies by 9,314.0% during the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock worth $37,730,000 after acquiring an additional 520,560 shares during the period. 24.39% of the stock is currently owned by institutional investors.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Directors Kurzius and Paul Keel reportedly purchased approximately $539,100 and $250,000 of COO shares, respectively. Insider buying can signal that company executives view the recent weakness as an attractive entry point. Cooper Companies Director Kurzius Buys Shares Director Paul Keel Buys Stock
• Neutral Sentiment: Barclays raised its rating to “Hold,” following coverage at an equal-weight stance. The move is less bearish than a sell recommendation but does not provide a strong bullish catalyst. Barclays Raises Cooper Companies Rating
• Neutral Sentiment: Cooper’s latest results showed an earnings-per-share beat, but revenue came in below analyst expectations and growth was modest. Full-year earnings guidance remains in place, leaving investors focused on whether the company can accelerate sales growth.
• Negative Sentiment: Rosen Law Firm is continuing an investigation into potential securities claims involving Cooper, alleging that the company may have issued materially misleading information to investors. Such announcements can increase legal, financial and reputational risks. Rosen Law Firm Investigation
• Negative Sentiment: Pomerantz LLP also announced an investigation on behalf of COO investors. The second law-firm announcement reinforces litigation concerns and is likely contributing to pressure on the shares, despite the allegations not being proven. Pomerantz Investor Investigation

About Cooper Companies

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.